Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH
Patent Improves Differentiated Profile of Ameluz-PDT by Expected Reduced Pain Intensity while Maintaining Efficacy WOBURN, Mass., Aug. 01, 2022 (GLOBE...
Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement
WOBURN, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence
Named Among the 10 Fastest-Growing Life Sciences Companies to Watch in 2022 by CIOCoverage Magazine New Ameluz® Marketing Campaign Receives Gold 2022...
Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference
WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...